Clopidogrel thrombocytopenia with

In addition to the risk of bleeding, which will be detailed in the different studies, thienopyridines are able to cause skin disorders (rashes or prurit) and gastrointestinal disorders (diarrhea). In the CLASSICS study, these side effects were observed in 8.2% of patients treated with ticlopidine and in 3.5% of those taking clopidogrel treatment. The most serious problem was related to hematologic disorders neutropenia or thrombocytopenia. These disorders are much less frequent with clopidogrel than with ticlopidine 0.04% of neutropenia in the CAPRIE study and 0.05% in the CURE trial, Thrombotic thrombocytopenic purpura are exceptional one for 200,000 patients. 

Abciximab STEMI (27), unstable angina (28),elective PCI (29) 0.25mg/kg followed by 0.125 xg/kg/min infusion Benefit in low/intermediate risk patients following clopidogrel pretreatment debated (39,40) Significant benefit (27-29) especially with respect to mortality (27) and reinfarction (27,28) Increased risk of major bleeding and thrombocytopenia compared to other Gp Ilb/IIIa inhibitors (33)... 

---